Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

@article{Cox2006GlycanOO,
  title={Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor},
  author={Kevin M. Cox and Jason D. Sterling and Jeff T. Regan and John R. Gasdaska and Karen Frantz and Charles G. Peele and Amelia Black and David Passmore and Cristina Moldovan-Loomis and Mohan Srinivasan and Severino Cuison and Pina M. Cardarelli and Lynn F. Dickey},
  journal={Nature Biotechnology},
  year={2006},
  volume={24},
  pages={1591-1597}
}
N-glycosylation is critical to the function of monoclonal antibodies (mAbs) and distinguishes various systems used for their production. We expressed human mAbs in the small aquatic plant Lemna minor, which offers several advantages for manufacturing therapeutic proteins free of zoonotic pathogens. Glycosylation of a mAb against human CD30 was optimized by co-expressing the heavy and light chains of the mAb with an RNA interference construct targeting expression of the endogenous α-1,3… Expand
Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern.
TLDR
The results demonstrate the feasibility of a knockout strategy for N-glycan engineering of plants towards mammalian-like structures, thus providing a significant improvement in the use of plants as an expression platform. Expand
Expression of a Glyco-Optimized Anti-CD20 Antibody in the Aquatic Plant Lemna with Enhanced ADCC Activity.
TLDR
The glyco-optimized rituximab showed enhanced ADCC with effector cells from all FcgRIIIa-158 genotypes and may offer the potential for an optimized anti-CD20 antibody therapeutic with improved efficacy and potency while simultaneously decreasing the side effects associated with CDC activity. Expand
Engineering of human-type O-glycosylation in Nicotiana benthamiana plants
TLDR
The tool-box for glyco-engineering in the tobacco related species Nicotiana benthamiana is extended toward the production of tailored mucin-type O-glycans on recombinant proteins. Expand
Rapid High Yield Production of Different Glycoforms of Ebola Virus Monoclonal Antibody
TLDR
The method described here allows the efficient generation of a series of different human-like glycoforms at large homogeneity of virtually any antibody within one week after cDNA delivery to plants. Expand
A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits.
TLDR
The results provide evidence for the adverse potential of nonmammalian N-glycan modifications present on monoclonal antibodies produced in plants, emphasizing the need for the use of glyco-engineered plants lacking any potentially antigenic N- glycan structures for the production of plant-derived recombinant proteins intended for parenteral human application. Expand
Main Strategies of Plant Expression System Glycoengineering for Producing Humanized Recombinant Pharmaceutical Proteins
TLDR
This review examines in detail the similarities and differences between N- and O–glycosylation in plant and mammalian cells, as well as the effect of plant glycans on the activity, pharmacokinetics, immunity, and intensity of biosynthesis of pharmaceutical proteins. Expand
Glycosylation of plant produced human antibodies.
TLDR
A plant based expression platform enabling engineering of antibody glycans provides a viable approach to the generation of antibodies with defined glycoforms on demand, contributing to studies on antibody glycANS and the development of novel antibody based drugs. Expand
Growth phase-dependent expression of proteins with decreased plant-specific N-glycans and immunogenicity in tobacco BY2 cells
TLDR
This study may provide a simple but effective strategy for the production of therapeutic glycoproteins with human-like N-glycan structures in plant hosts to avoid a great allergenic risk. Expand
Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.
TLDR
RNAi technology was used to obtain a targeted down-regulation of the endogenous beta1,2-xylosyl transferase (XylT) and alpha1,3-fucosyltransferase (FucT) genes in Nicotiana benthamiana, a tobacco-related plant species widely used for recombinant protein expression, providing a robust tool for the production of therapeutically relevant glycoproteins in plants with a humanized N-glycan structure. Expand
Challenges in O-glycan engineering of plants
TLDR
Important issues that have to be addressed in the future are elimination of potentially immunogenic or allergenic carbohydrate epitopes containing arabinosides or arabinogalactans and a deeper understanding of signals and mechanisms for distribution of glycan processing enzymes, which is a prerequisite for complete and homogenous glycosylation of recombinant proteins. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
An antibody produced in tobacco expressing a hybrid β-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes
TLDR
It is demonstrated that expression of a hybrid enzyme in tobacco causes a sharp reduction of N-glycans with potentially immunogenic core-bound xylose and fucose residues, which suggests that a transgenic plant expressing the hybrid GalT might yield more effective and safer monoclonals for therapeutic purposes than WT plants and even transgenic plants expressing the unchanged GalT. Expand
Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans.
TLDR
A strict retention of glycoproteins to ER by the use of the tetrapeptide KDEL was not sufficient, even though the majority of the resulting N-glycosylation was of the high-mannose type, and is highly likely to be dependent on other factors, which are most probably protein specific. Expand
Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin.
TLDR
Experiments with sera from allergic patients suggest that glycomodified human transferrin, especially the MMXF glycoform, is a suitable reagent for the detection of antibodies against cross-reactive carbohydrate determinants. Expand
Biopharmaceutical production in plants: problems, solutions and opportunities.
TLDR
To exploit fully the potential that plants offer for the production of therapeutic proteins for parenteral administration, it might be necessary to inhibit plant-specific post-translational modifications to obtain "humanized" non-immunogenic N-glycans on PMPs. Expand
N‐Glycosylation in the Moss Physcomitrella patens is Organized Similarly to that in Higher Plants
TLDR
It is concluded that the N-glycosylation pathway in P. patens is identically organized to that in higher plants, and since complex type structures appear more desirable than oligomannosidic N- glycans, future modifications of the pathway should target α1,3-fucosyl transferase and/or β1,2-xylosyltransferase. Expand
Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures.
TLDR
It appears that alfalfa plants have the ability to produce recombinant IgG1 having a N-glycosylation that is suitable for in vitro or in vivo glycan remodelling into a human-compatible plantibody. Expand
Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans
TLDR
It is demonstrated that transgenic plants can be used to produce high affinity, monoclonal secretory antibodies that can prevent specific microbial colonization in humans, and these findings could be extended to the immunotherapeutic prevention of other mucosal infections in humans and animals. Expand
Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves.
TLDR
Senescence was shown to affect the glycosylation profile of endogenous proteins and major differences were observed between glycan structures on endogenous proteins versus those on antibodies, probably to be attributed to their subcellular localization. Expand
A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes
TLDR
This work compared a humanized anti–herpes simplex virus 2 (HSV-2) Mab expressed in mammalian cell culture with the same antibody expressed in soybean to find these Mabs to be similar in their stability in human semen and cervical mucus over 24 h, their ability to diffuse in human cervical mucUS, and their efficacy for prevention of vaginal HSV- 2 infection in the mouse. Expand
N-linked glycan structures of a mouse monoclonal antibody produced from tobacco BY2 suspension-cultured cells.
TLDR
The major glycan structures of the antibodies produced by transgenic suspension-cultured cells contain typical plant bisecting beta( 1,2)-xylose and alpha(1,3)-fucose residues, suggesting the posttranslational modification of a recombinant antibody in the late Golgi apparatus. Expand
...
1
2
3
4
...